Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial
Tamiru Shibiru Degaga(Charles Darwin University), Geremew Gashaw Gessa(Arba Minch University), Anjana Rai, Amna Ibrahim(Beni-Suef University), Taj Muhammad(Aga Khan University), Sarah A. Cassidy-Seyoum(Charles Darwin University), Dagimawie Tadesse Abate(Arba Minch University), Halik Hadi(Universitas Sumatera Utara), Meas Sokha(Mahidol University), Mom Ean(Mahidol University), Sophie Weston(University of Oxford), Angela Rumaseb(Charles Darwin University), Tedla Teferi Tego(Arba Minch University), Benedikt Ley(Charles Darwin University), Ayodhia Pitaloka Pasaribu(Universitas Darma Agung), Rodas Temesgen(Arba Minch University), Angela Devine(Charles Darwin University), Yulita Yulita(Indonesian Coral Reef Foundation), Nasreen A. Syed(Aga Khan University), Grant Lee(Charles Darwin University), Hellen Mnjala(Charles Darwin University), Rupam Tripura(Mahidol University), Robert J. Commons(Charles Darwin University), Megha Rajasekhar(The University of Melbourne), James J. Callery(Mahidol Oxford Tropical Medicine Research Unit), Bushra Qurashi(Aga Khan University), Pinkan Kariodimedjo, Peixuan Li(The University of Melbourne), Umair Shoukat Ali(Aga Khan University), Ery Setiawan(Charles Darwin University), F. Jabbar(Aga Khan University), Samuel Alemu Bamboro(Arba Minch University), Nurfadhilah Hasibuan(Indonesian Coral Reef Foundation), Widaya Safitri(Indonesian Coral Reef Foundation), Dedi Sahat Parningotan Siagian(Universitas Baturaja), Deni Syahputra(Universitas Baturaja), Khuda Dost(Aga Khan University), Eyerusalem Beyene Erjabo(Arba Minch University), Agatha Mia Puspitrasari, Asia Khan(Aga Khan University), Shane Zehra(Aga Khan University), Tariq Mehmood(Aga Khan University), Najia Ghanchi(Aga Khan University), Tom Peto(Mahidol Oxford Tropical Medicine Research Unit), Rintis Noviyanti(Eijkman Institute for Molecular Biology), Abdul Momin Kazi(Aga Khan University), Arjen Dondorp(Mahidol Oxford Tropical Medicine Research Unit), Edwin Sutanto(Charles Darwin University), Bipin Adhikari(Mahidol Oxford Tropical Medicine Research Unit), Muthoni Mwaura(Charles Darwin University)
Cited by 8
Related Papers
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
|Clinical Cancer Research|2015|532
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
|Clinical Cancer Research|2015|377
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
|Clinical Cancer Research|2014|350
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
|Journal of Clinical Oncology|2019|348